Thew Graham R, Kwok Amy P L, Lissillour Chan Mandy H, Powell Candice L Y M, Wild Jennifer, Leung Patrick W L, Clark David M
Department of Experimental Psychology, University of Oxford, UK.
Oxford University Hospitals NHS Foundation Trust, UK.
Internet Interv. 2022 Apr 18;28:100539. doi: 10.1016/j.invent.2022.100539. eCollection 2022 Apr.
Research is needed to determine the extent to which internet-delivered psychological therapies are effective when delivered in countries and cultures outside of where they were developed.
This waitlist-controlled study evaluated the efficacy of a UK-developed, therapist-guided internet Cognitive Therapy programme for Social Anxiety Disorder (iCT-SAD) when delivered in Hong Kong by local therapists.
Patients were randomized to iCT-SAD (n = 22) or a waitlist control group (n = 22). Assessments took place at weeks 0, 8, and 15 (posttreatment/postwait), with a further 3-month follow-up assessment for the iCT-SAD group. The primary outcome measure was the Liebowitz Social Anxiety Scale (self-report), and posttreatment/postwait diagnostic assessments were completed by independent assessors blind to condition. Trial Registration: ISRCTN11357117.
Compared with the waitlist group, iCT-SAD significantly reduced social anxiety symptoms (adjusted difference at posttreatment 55.36, 95%CI 44.32 to 66.39, < 0.001; 2.41). The treatment was also superior to waitlist on all secondary outcome measures. 86% of the iCT-SAD group demonstrated remission from SAD based on the LSAS, compared to 5% of the waitlist group. 73% no longer met diagnostic criteria at posttreatment, compared to 9% of the waitlist group. The gains made by the iCT-SAD group were maintained at three-month follow-up.
iCT-SAD showed strong efficacy for the treatment of SAD in Hong Kong. As the clinical outcomes were similar to UK studies, this suggests the dissemination of the treatment into a different cultural setting did not result in a substantial loss of efficacy.
需要开展研究以确定在其研发地以外的国家和文化中提供互联网心理疗法时,其有效程度如何。
这项等待名单对照研究评估了由英国研发、治疗师指导的社交焦虑障碍互联网认知疗法项目(iCT-SAD)在香港由当地治疗师提供时的疗效。
患者被随机分为iCT-SAD组(n = 22)或等待名单对照组(n = 22)。在第0、8和15周(治疗后/等待后)进行评估,对iCT-SAD组进行为期3个月的随访评估。主要结局指标是利博维茨社交焦虑量表(自我报告),治疗后/等待后的诊断评估由对治疗情况不知情的独立评估者完成。试验注册号:ISRCTN11357117。
与等待名单组相比,iCT-SAD显著减轻了社交焦虑症状(治疗后调整差异为55.36,95%置信区间为44.32至66.39,<0.001;Cohen's d = 2.41)。在所有次要结局指标上,该治疗也优于等待名单组。根据LSAS,iCT-SAD组86%的患者社交焦虑障碍症状缓解,而等待名单组为5%。治疗后,73%的患者不再符合诊断标准,而等待名单组为9%。iCT-SAD组取得的疗效在3个月随访时得以维持。
iCT-SAD在香港治疗社交焦虑障碍显示出强大疗效。由于临床结果与英国的研究相似,这表明将该治疗推广到不同文化背景中并未导致疗效大幅下降。